ArcticZymes Technologies (AZT) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue reached NOK 31.9 million, up 19% year-over-year, with strong growth in both Molecular Tools and Biomanufacturing segments and broad-based customer demand.

• EBITDA for Q2 was NOK 7.4 million, up 90% year-over-year, with EBITDA margin improving to 23% and net profit at NOK 5.3 million.

• First half 2026 revenue totaled NOK 63.7 million, up 27% year-over-year, with both segments contributing nearly equally.

• Strategic focus on expanding into CDMOs, RNA IVT workflow, and diversification across applications and geographies, with a transition to a customer-centric, application-led solutions provider.

• Significant milestones include onboarding a new CDMO, a customer’s FDA PMA approval for a cancer screening test embedding the company’s enzyme, and innovation in RNA enzymes.

Financial highlights

• Q2 sales revenue: NOK 31.9 million (+19% YoY); total revenue: NOK 33.9 million (+17% YoY); constant currency revenue would have been NOK 34.6 million (+29% YoY).

• First half sales revenue: NOK 63.7 million (+27% YoY); constant currency NOK 69.3 million (+39% YoY).

• EBITDA Q2: NOK 7.4 million (margin 23%, up from 15% last year); H1 EBITDA: NOK 9.0 million (H1 2025: NOK 0.1 million).

• Net profit: NOK 5.3 million in Q2; EPS: NOK 0.10.

• Cash and short-term investments at quarter-end: NOK 269 million, with positive operating cash flow of NOK 8.1 million in H1.

Outlook and guidance

• Ambition for sustainable double-digit growth, aiming to outperform served markets and expand EBITDA margin.

• Continued investment in commercial organization, innovation, and RNA therapeutics as a growth pillar.

• Focus on diversification and expanding into new application areas, including metagenomics and RNA IVT workflow.

• Visibility of several programs moving from evaluation to supply in H2, supporting confidence in future growth.

• Commercial and operational planning remains flexible to adapt to macroeconomic and geopolitical uncertainties.